Company Analysis

Ovid Therapeutics Inc. (OVID)

Nasdaq: OVID · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2015
Grade5.8
◀ Past 4.2● Present 5.7▶ Future 6.9
1 est.

Who runs Ovid Therapeutics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Alexander Margaret A.
President and CEO. First filing Sep 2024, latest Mar 2, 2026, 3 filings in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
20 people on the record since 2017
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Carter Charles RossChief Financial OfficerJul 2026Jul 8, 2026none
Levin Jeremy MExecutive ChairmanMay 2017Mar 25, 2026none
Alexander Margaret A.President and CEOSep 2024Mar 2, 20261 · $0.00
Rona Jeffrey ACBFOOct 2020Mar 2, 20261 · $0.00
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Greka AnnadirectorJun 2026Jun 17, 2026none
Fitzgerald Kevin JosephdirectorOct 2021Apr 9, 2026none
Friedman BartdirectorMay 2017Apr 9, 2026none
Papadopoulos SteliosdirectorMar 2025Apr 9, 2026none
Bernstein KarendirectorMay 2017Mar 2, 2026none
Duncan Barbara GayledirectorJun 2017Mar 2, 2026none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Takeda Pharmaceutical Co Ltd10% ownerOct 2019Dec 9, 2025none
Takeda Pharmaceuticals U.S.A., Inc.10% ownerJul 2022Dec 9, 2025none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton OVID · research, not advice